Bluebird Stock Offering Lands $500M To Fund Drug Pipeline
Massachusetts-based Bluebird Bio Inc. raked in $500 million in a follow-on offering Tuesday, the day after the clinical-stage genetic and rare disease biotech inked a deal with Kite Pharma Inc. to...To view the full article, register now.
Already a subscriber? Click here to view full article